Cidara Therapeutics, Inc.

NasdaqCM:CDTX Stock Report

Market Cap: US$254.0m

Cidara Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Cidara Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-94.1%

Buyback Yield

Total Shareholder Yield-94.1%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17
Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Mar 14
We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara spikes on $11M milestone payment from partner Mundipharma

Oct 04

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Sep 13

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17
Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17
Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Aug 04
Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?

Cidara Therapeutics: Rezafungin Data Could Bring Value

Jul 20

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if CDTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CDTX's dividend payments have been increasing.


Dividend Yield vs Market

Cidara Therapeutics Dividend Yield vs Market
How does CDTX dividend yield compare to the market?
SegmentDividend Yield
Company (CDTX)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.5%
Analyst forecast (CDTX) (up to 3 years)n/a

Notable Dividend: Unable to evaluate CDTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CDTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate CDTX's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CDTX has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 09:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cidara Therapeutics, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Timothy ChiangBTIG
Chiara RussoCantor Fitzgerald & Co.
Louise ChenCantor Fitzgerald & Co.